Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants

Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants

Inventiva (Euronext Paris and NASDAQ: IVA) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“ MASH ”), is pleased to announce the completion of the final step of the transactions previously announced on June 2, 2026 (the “ Combined Transaction ”) through the issuance of approximately 15.7 million new warrants ( bons de souscription d’actions ) (the " New EIB Warrants ") to the European Investment Bank (the " EIB ") and the surrender and cancellation of all remaining warrants originally issued to the EIB in January 2024 (the “ Legacy EIB Tranche B Warrants ”) that were not repurchased in the Combined Transaction.

Andrew Obenshain, CEO of Inventiva, commented : " The completion of this EIB warrant restructuring is an important step in strengthening Inventiva’s capital structure and improving alignment with our shareholders. By replacing the remaining legacy EIB warrants with a simplified warrant instrument that no longer includes specific contractual anti-dilution protection mechanisms, we have eliminated a potential source of future uncertainty and dilution. This achievement, together with the previously announced broader refinancing, provides Inventiva with increased financial flexibility as we continue advancing the development of lanifibranor, our investigational pan-PPAR agonist for the treatment of MASH."

The issuance of the New EIB Warrants forms part of the comprehensive refinancing transaction previously announced by the Company and marks the completion of the EIB warrant restructuring, a key step i...